Key result
Low-dose epoetin-β following PCI significantly improved global ejection fraction compared to placebo (ΔEF 5.2% vs 0.3%; P=0.019).
Why the study?
Does low-dose epoetin-β improve ejection fraction in patients with symptomatic ischaemic heart failure following percutaneous coronary intervention?
RCT (n=24)
Double-blind
Randomized
No
Does low-dose epoetin-β improve ejection fraction in patients with symptomatic ischaemic heart failure following percutaneous coronary intervention?
Absolute Event Rate: 5.2% vs 0.3%
p-value: p=0.019
In a pilot study, low-dose epoetin-β administered for 6 months following PCI in patients with symptomatic ischaemic heart failure was safe and significantly improved global ejection fraction.
Authors
No takes yet. Share an insight, caveat, or question.
Supports low-dose epoetin-β to improve EF after PCI in ischaemic HF; extends randomized evidence but requires larger confirmatory trials.
Bergmann et al. (2011) conducted an RCT in Symptomatic ischaemic heart failure (n=24). Epoetin-β vs. Placebo was evaluated on Individual change in ejection fraction (p=0.019). Low-dose epoetin-β following PCI significantly improved global ejection fraction compared to placebo (ΔEF 5.2% vs 0.3%; P=0.019).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: